|

TARA-002 Clinical Trials

2 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Protara Therapeutics2

Indications

  • Cancer2
  • Non-Muscle Invasive Bladder Carcinoma1
  • Non-muscle Invasive Bladder Cancer With Carcinoma in Situ1
  • Bladder (Urothelial, Transitional Cell) Cancer1
  • Non-Muscle Invasive Bladder Cancer1

Homewood, Alabama1 trial

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Urology Centers of Alabama

Phase 2

Queen Creek, Arizona1 trial

Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer

East Valley Urology Center of Arizona

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.